Adalimumab (Humira®) and Biosimilars

Adalimumab is a biologic drug product that is launched by Abbvie and is approved for medical use in the United States in 2002. This drug is originally sold under the brand name Humira®. Adalimumab is a fully human monoclonal antibody that functions by blocking soluble and transmembrane TNF-α (tumor necrosis factor-alpha) which causes inflammation in the body. This drug has been used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. So far, a few adalimumab (Humira®) biosimilars have been approved in the market including Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hyrimoz (adalimumab-adaz), Hadlima (adalimumab-bwwd), Abrilada (adalimumab-afzb), Hulio (adalimumab-fkjp), Yusimry (adalimumab-aqvh), Idacio (adalimumab-aacf) and Yuflyma (adalimumab-aaty). Adalimumab is produced by recombinant DNA technology using a mammalian cell expression system.

RGBiotech offers adlimumab expressing plasmid vectors to assist your biosimilar development.

Product Name: pBD-hFerL(H)-Adalimumab(Neo) Plasmid Vector

Item No.: PPBD-3-1

Plasmid Vector Map:

Quality Control:

Contact Us